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WHAT SHOULD WE KNOW ABOUT HYPERSENSITIVITY TO 
PEANUTS IN TOPICAL PREPARATIONS
	 The	 rising	prevalence	of	 food	allergies	poses	
an	increasingly	important	clinical	problem.	Peanut	
is	one	of	 the	most	potent	allergens,	and	allergic	
reactions	 to	 peanuts	 may	 even	 be	 fatal.	A	 great	
proportion	 of	 hypersensitive	 individuals	 manifest	
allergic reaction on their first exposure to peanut 
containing food, pointing to pre-existing sensitiza-
tion.	Therefore,	the	question	arises	whether	pea-
nut	containing	topical	preparations	are	safe	or	epi-
cutaneous sensitization is still possible.
	 A	 considerable	 increase	 in	 the	 prevalence	 of	
allergic	 diseases	 has	 been	 recorded	 in	 the	 past	
few decades, in industrialized countries in particu-
lar.	 This	 increasing	 tendency	 primarily	 refers	 to	
type	 I	allergic	diseases	such	as	allergic	asthma,	
allergic	 rhinoconjunctivitis	 and	 atopic	 dermatitis.	
Such a significantly rising tendency has not been 
recorded	for	other	 types	of	allergic	disease	such	
as cytotoxic reactions (type II), immune complex 
diseases (type III) and delayed immune response 
reactions (type IV) (1).
	 The	 rise	 in	 the	 prevalence	 of	 food	 allergies	
poses	a	major	clinical	problem.	Considering	vari-
ous	 foodstuffs,	peanut	 is	one	of	 the	most	potent	
allergens, as 1% of the Western world populations 
suffer from peanut hypersensitivity (2). Clinical 
manifestations	of	peanut	allergy	are	variable,	from	
urticaria,	gastrointestinal	and	respiratory	discom-
forts	 through	 severe	 clinical	manifestations	 such	
as anaphylactic shock (3). Peanuts account for as 
many as 63% of fatal food allergic reactions (4).
Peanut	contains	proteins	that	are	responsible	for	
its	high	allergenic	potency.	A	number	of	proteins	
have been isolated and identified as peanut aller-
gens, designated Ara h 1 – Ara h 8 (4) after the 
Latin	 name	 of	 the	 plant,	 Arachis hypogaea (5). 
Some	 of	 these	 protein	 clones	 have	 now	 been	
synthesized (6). The minimal amount of the pro-
tein	considered	adequate	 to	cause	allergic	 reac-
tion is 50-100 mg (7). Peanut oils may pose great 
problem in sensitized individuals due to residual 
protein	they	contain,	depending	on	the	manufac-
turing technology. Refined oils contain 100 times 
less protein than non-refined ones (5,7). In a study 
conducted in Great Britain, none of the 60 subjects 
with	known	peanut	allergy	showed	allergic	 reac-
tion upon refined oil intake, whereas six (10%) in-
dividuals	developed	allergic	reaction	upon	non-re-
fined oil intake (7). Similar studies were performed 
with	soybean	oils,	and	none	of	the	study	subjects	
developed allergic reaction (8).
 Although one could infer thereof that refined oils 
are	safe	for	use	by	individuals	allergic	to	peanuts,	
great	 caution	 is	 warranted	 because	 of	 the	 pos-
sible	 “contamination”	 of	 these	 products	 through	
their	repeated	use	in	food	preparation,	due	to	re-
sidual	protein	 from	 the	previously	prepared	 food	
(7). Cases have been described of anaphylactic 
reaction	 caused	 by	 the	 use	 of	 peanut	 contami-
nated	objects	or	through	contact	between	peanut	
contaminated	hands	and	saliva	in	individuals	with	
known peanut hypersensitivity (9).
 When talking about peanut hypersensitivity, the 
possible	cross	reaction	with	soy	should	always	be	




In Sweden, six fatal cases of anaphylactic food re-
actions,	two	of	them	peanut	allergy	and	four	soy-
bean allergy, were recorded during the 1993-1996 
period.	Allergic	 reaction	 to	 soy	 proteins	 was	 not	
previously	known	in	any	of	the	four	cases	of	soy-
bean	allergy,	while	peanut	allergy	was	previously	
known in all these subjects (10). In 72%-81% of 
cases,	the	individuals	with	peanut	allergy	manifest	
it upon the first intake of this allergen (11,12). As it 
is an IgE-mediated allergic reaction (type I), which 
requires previous allergen sensitization, the ques-
tion arises of the possible sensitization by some 
other	than	oral	route.
 Sensitization in utero	 may	 be	 possible,	 how-
ever,	 there	 are	 no	 studies	 to	 demonstrate	 it.	 In	
a study carried out in Toronto, Canada, in 1999-
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2000, peanut proteins were detected in breast milk 
of	 lactating	 women	 taking	 peanuts,	 thus	 sensiti-
zation via breast-feeding	is	considered	as	one	of	
the possible routes of sensitization (11). The more 
so, there are some controversial studies (13), and 
an	open	question	 is	whether	breast-feeding	may	




pointing to the possible epicutaneous sensitiza-
tion	in	allergy	predisposed	individuals.	Besides	its	
wide use in food industry, peanut oil (oleum ara-
chidis) is frequently used in pharmaceutical indus-




eficial effect of peanut oil in the form of oil baths, 
free	 from	 any	 side	 effects	 recorded,	 was	 espe-
cially	pronounced	in	the	treatment	of	very	dry	and	
damaged skin (e.g., eczema) both in adults and in 
children (3). However, the official statement of the 
European	Agency	for	the	Evaluation	of	Medicinal	
Products (EMEA) from January 12, 2006, pres-
ents	reports	of	skin	reactions	that	may	have	been	
related	to	the	use	of	oil	baths	containing	peanut	or	
soybean oil (14). A retrospective British study (15) 
demonstrated	the	association	between	type	I	hy-
persensitivity	reaction	to	peanut	and	previous	skin	
exposure, i.e. use of topical preparations based on 
peanut oil. It is considered that as many as 95% 
of	individuals	with	peanut	hypersensitivity	have	a	
history of previous exposure to topical prepara-
tions containing peanut oil, especially in the first 





of the possible epicutaneous sensitization and 
subsequent	 induction	 of	 Th-2	 immune	 response	
we refer to the experimental model employed by 
Strid	et al. (12). In this study, mice were adminis-
tered	a	topical	peanut	based	preparation	following	
epidermal	damage	caused	by	self-adhering	tape,	
corresponding	 to	 the	 skin	 with	 protective	 barrier	
impairment. The levels of IL-4 and IgE showed 
a	 considerable	 increase	 when	 the	 mice	 started	
receiving	 peanut	 based	 chow.	 Initially,	 the	 level	
of	 IFN-γ	 was	 also	 elevated,	 indicating	 that	 the	
immune response was still of a mixed Th-1 and 
Th-2	type,	with	subsequent	predominance	of	Th-
2	type	response.	In	addition,	the	development	of	
otherwise expected oral peanut tolerance was pre-
vented,	with	 impairment	of	 the	already	achieved	
oral	 tolerance.	 In	 adults,	 even	 daily	 washing,	
shaving, frequent use of exfoliating preparations, 
depilation	 preparations,	 etc.	 may	 lead	 to	 impair-
ment of the protective skin barrier (12).
	 Although	 the	EMEA	statement	 is	 that	skin	 re-
actions	which	can	be	related	to	the	use	of	topical	








known peanut and soybean allergy (14).
 In conclusion, peanut sensitization is an impor-
tant	and	increasing	clinical	problem	due	to	the	se-
vere	allergic	manifestations	that	may	threaten	the	
life of sensitized individuals. Topical preparations 
containing peanut oil have proved efficient in the 
treatment	 of	 very	 dry	 and	 damaged	 skin	 in	 chil-
dren	and	adults	with	atopic	diseases.	Epicutane-
ous sensitization is one of the potential routes of 
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